HIGH-GRADE B-CELL LYMPHOMA

This study tests whether adding three targeted antibodies (tafasitamab, retifanlimab, and rituximab) to standard chemotherapy can safely and effectively treat adults with untreated diffuse large B-cell lymphoma. The goal is to improve cancer-killing power while managing side effe…

This study tests whether the drug acalabrutinib can help prevent relapse in people with very high-risk large B-cell lymphoma after they have received cell therapy (stem cell transplant or CAR T-cells). About 24 adults aged 18-70 will take acalabrutinib as a maintenance treatment.…

This early-phase study tests a new type of CAR T cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It is for people with non-Hodgkin lymphoma that has come back or not responded to standard treatments. The main goals are to check safety and find the right…

This early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells. The main…

This study tests whether adding either tazemetostat or zanubrutinib to a standard two-drug therapy (tafasitamab and lenalidomide) can better control relapsed or refractory large B-cell lymphoma in people who are not eligible for a stem cell transplant. About 227 participants will…

This early-stage study tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have returned or not improved with standard treatments. The therapy uses a harmless virus to deliver a gene that helps the immune system attack c…

This early-phase study tests a new drug called AZD0486 in about 227 people with B-cell non-Hodgkin lymphoma, including types like diffuse large B-cell and follicular lymphoma. The drug is a special antibody that helps the immune system attack cancer cells. The main goals are to c…

This early-phase study tests a new drug called SGR-1505 in about 98 adults with various B-cell blood cancers (like lymphoma and leukemia). The main goals are to check safety and find the best dose. Participants will receive the drug and be monitored for side effects and how the d…

This study tests whether the drug emapalumab can prevent severe cytokine release syndrome (CRS), a common and serious side effect of CAR-T cell therapy, in adults with certain types of non-Hodgkin lymphoma that have come back or not responded to treatment. About 28 participants w…

This early-phase study tests whether adding a drug called mosunetuzumab after a stem cell transplant is safe and doable for people with aggressive B cell lymphoma that has come back or not responded to prior treatments. Mosunetuzumab is an engineered antibody that helps the body'…

This early-phase trial tests a new treatment called CLIC-2201 for people with certain blood cancers (like lymphoma or leukemia) that have not responded to standard therapy or have returned. The treatment uses a patient's own immune cells, which are modified in a lab to better rec…

This study is for people aged 65 and older with diffuse large B-cell lymphoma (DLBCL) or similar lymphomas. The goal is to see if adding the drug glofitamab to standard chemotherapy can improve treatment results with fewer side effects. About 42 participants will receive a combin…

This study tests whether adding the immunotherapy drug mosunetuzumab to standard chemotherapy is safe and effective for people with a fast-growing type of lymphoma that has a specific genetic change (c-Myc rearrangement). About 30 adults aged 18-75 who have not yet been treated w…

This early-phase trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) in about 30 adults with diffuse large B-cell lymphoma that has come back or not responded to prior therapy. The main goal is to find the safest dose and see if the com…

This study looks at whether a new blood test (ctDNA) can guide doctors to safely give less chemotherapy to certain patients with a type of lymphoma called DLBCL. About 40 newly diagnosed patients will have their blood tested during standard treatment. If the test shows no cancer …

This study watches how older patients (age 60 and up) with certain blood cancers handle standard CAR-T cell therapy and how it changes their daily life and thinking skills. No extra treatment is given—just careful checkups. The goal is to see if patients can complete all planned …

This study looks at how changes in the MYC gene relate to the immune environment and treatment outcomes in people with diffuse large B-cell lymphoma or high-grade B-cell lymphoma. Researchers will collect data from 200 patients to understand these links better. No new treatments …

This study looks at whether a new DNA test on spinal fluid can find signs of lymphoma spreading to the brain before standard tests do. About 50 people with aggressive B-cell lymphoma at high risk for brain relapse will give spinal fluid samples during their first treatment. The g…